Published in Eur J Immunol on December 01, 1994
Lag-3 and Gemcitabine for Treatment of Advanced Pancreas Cancer | NCT00732082
LAG-3 regulates plasmacytoid dendritic cell homeostasis. J Immunol (2009) 1.33
The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells. Immunology (2005) 1.27
Characterization of the major histocompatibility complex class II binding site on LAG-3 protein. Proc Natl Acad Sci U S A (1997) 1.14
Role of lymphocyte activation gene-3 (Lag-3) in conventional and regulatory T cell function in allogeneic transplantation. PLoS One (2014) 0.96
Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease. Immunity (2016) 0.88
A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma. Invest New Drugs (2012) 0.88
Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview. Urol Oncol (2016) 0.86
Role of 4-1BB receptor in the control played by CD8(+) T cells on IFN-gamma production by Mycobacterium tuberculosis antigen-specific CD4(+) T Cells. PLoS One (2010) 0.83
Immune checkpoints and immunotherapy for colorectal cancer. Gastroenterol Rep (Oxf) (2015) 0.83
Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy. Mol Oncol (2015) 0.79
LAG-3 (CD223) reduces macrophage and dendritic cell differentiation from monocyte precursors. Immunology (2005) 0.78
LAG3 (CD223) as a cancer immunotherapy target. Immunol Rev (2017) 0.77
New clinical advances in immunotherapy for the treatment of solid tumours. Immunology (2015) 0.76
Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. Oncoimmunology (2016) 0.75
Lymphocyte activation gene 3 and coronary artery disease. JCI Insight (2016) 0.75
Through the Immune Looking Glass: A Model for Brain Memory Strategies. Front Cell Neurosci (2016) 0.75
LAG-3 confers poor prognosis and its blockade reshapes antitumor response in head and neck squamous cell carcinoma. Oncoimmunology (2016) 0.75
T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature (1985) 21.57
Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med (2001) 5.71
Generation of monoclonal antibodies to a human natural killer clone. Characterization of two natural killer-associated antigens, NKH1A and NKH2, expressed on subsets of large granular lymphocytes. J Clin Invest (1985) 2.77
Surface structures involved in target recognition by human cytotoxic T lymphocytes. Science (1982) 2.52
A gamma-chain complex forms a functional receptor on cloned human lymphocytes with natural killer-like activity. Nature (1987) 2.48
Characterization of an antigen expressed by human natural killer cells. J Immunol (1983) 2.44
Subpopulations of human peripheral T gamma delta lymphocytes. Immunol Today (1989) 2.39
The human T-cell receptor. Annu Rev Immunol (1984) 2.23
A novel subset of human lymphocytes with a T cell receptor-gamma complex. J Exp Med (1987) 2.12
Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies. Acta Psychiatr Scand (2009) 2.07
An experimentally validated panel of subfamily-specific oligonucleotide primers (V alpha 1-w29/V beta 1-w24) for the study of human T cell receptor variable V gene segment usage by polymerase chain reaction. Eur J Immunol (1992) 2.03
Phenotypic and functional heterogeneity of human cloned natural killer cell lines. Nature (1983) 1.93
A unique T-cell receptor complex expressed on human fetal lymphocytes displaying natural-killer-like activity. Nature (1986) 1.90
Analysis of T-cell receptor gene rearrangement and expression in human natural killer clones. Science (1985) 1.83
LAG-3, a novel lymphocyte activation gene closely related to CD4. J Exp Med (1990) 1.83
SOFA--an open source framework for medical simulation. Stud Health Technol Inform (2007) 1.81
A novel human V delta gene expressed predominantly in the Ti gamma A fraction of gamma/delta+ peripheral lymphocytes. Eur J Immunol (1988) 1.76
T cell receptor gamma/delta+ lymphocyte subsets during HIV infection. Clin Exp Immunol (1989) 1.72
Effects of cannabis and psychosis vulnerability in daily life: an experience sampling test study. Psychol Med (2003) 1.67
Sequences and diversity of human T cell receptor beta chain variable region genes. J Exp Med (1986) 1.62
Identification of a clonally restricted 90 kD heterodimer on two human cloned natural killer cell lines. Its role in cytotoxic effector function. J Exp Med (1983) 1.62
A unique V-J-C-rearranged gene encodes a gamma protein expressed on the majority of CD3+ T cell receptor-alpha/beta- circulating lymphocytes. J Exp Med (1988) 1.61
Comparative expression of T9, T10, and Ia antigens on activated human T cell subsets. Hum Immunol (1981) 1.57
Generation of a cloned NK cell line derived from the "null cell" fraction of human peripheral blood. J Immunol (1982) 1.56
Studies on the human T cell receptor alpha/beta variable region genes. II. Identification of four additional V beta subfamilies. Eur J Immunol (1991) 1.53
Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens. J Exp Med (1992) 1.48
T-cell repertoires in healthy and diseased human tissues analysed by T-cell receptor beta-chain CDR3 size determination: evidence for oligoclonal expansions in tumours and inflammatory diseases. Res Immunol (1995) 1.44
Expression of different CD8 isoforms on distinct human lymphocyte subpopulations. Eur J Immunol (1991) 1.44
CD3/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3/TCR signaling. J Immunol (1998) 1.40
Characterization of human peripheral lymphocytes expressing the CD3-gamma/delta complex with anti-receptor monoclonal antibodies. J Immunol (1988) 1.40
CD1c as a target recognition structure for human T lymphocytes: analysis with peripheral blood gamma/delta cells. Eur J Immunol (1990) 1.36
T cells expressing gamma delta chain receptors in rheumatoid arthritis. J Autoimmun (1988) 1.32
Analysis of T cell receptor variability in tumor-infiltrating lymphocytes from a human regressive melanoma. Evidence for in situ T cell clonal expansion. J Clin Invest (1993) 1.32
Immunological study of in vitro maturation of human megakaryocytes. Br J Haematol (1984) 1.32
Characterization of functional surface structures on human natural killer cells. Adv Immunol (1988) 1.30
Further analysis of the T cell receptor gamma/delta+ peripheral lymphocyte subset. The V delta 1 gene segment is expressed with either C alpha or C delta. J Exp Med (1990) 1.29
Studies on the human T cell receptor alpha/beta variable region genes. I. Identification of 7 additional V alpha subfamilies and 14 J alpha gene segments. Eur J Immunol (1991) 1.29
Natural killer clones derived from fetal (25 wk) blood. Probing the human T cell receptor with WT31 monoclonal antibody. J Exp Med (1986) 1.21
Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand. Immunogenetics (1994) 1.19
Proliferative responses of circulating human NK cells: delineation of a unique pathway involving both direct and helper signals. Eur J Immunol (1985) 1.18
CD3/Ti gamma A: a functional gamma-receptor complex expressed on human peripheral lymphocytes. J Immunol (1988) 1.17
A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation. Eur J Immunol (1999) 1.16
CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins. Eur J Immunol (1995) 1.16
Direct evidence to support the immunosurveillance concept in a human regressive melanoma. J Clin Invest (1994) 1.16
Characterization of the major histocompatibility complex class II binding site on LAG-3 protein. Proc Natl Acad Sci U S A (1997) 1.14
Cloned human CD3- lymphocytes with natural killer-like activity do not express nor rearrange T cell receptor gamma genes. Eur J Immunol (1987) 1.13
Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound. J Biol Chem (1995) 1.13
Characterization of the T lymphocyte colony-forming cells and evidence for the acquisition of T cell markers in the absence of the thymic microenvironment in man. J Immunol (1981) 1.10
Autologous bone-marrow transplantation in CALLA-positive acute lymphoblastic leukemia after in-vitro treatment with J5 monoclonal antibody and complement. Lancet (1982) 1.10
Characteristics and uses of natural killer cells. Immunol Today (1988) 1.09
4-Hydroxyisoleucine: experimental evidence of its insulinotropic and antidiabetic properties. Am J Physiol (1999) 1.09
T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell-cell contacts. Eur J Cancer (2001) 1.08
Evidence for in situ amplification of cytotoxic T-lymphocytes with antitumor activity in a human regressive melanoma. Cancer Res (1993) 1.07
A hsp70-2 mutation recognized by CTL on a human renal cell carcinoma. J Immunol (1999) 1.06
A layered model of a virtual human intestine for surgery simulation. Med Image Anal (2004) 1.05
Analysis of T-cell receptor alpha/beta variability in lymphocytes infiltrating a melanoma metastasis. Cancer Res (1992) 1.04
Dihydroorotate dehydrogenase is a target for the biological effects of leflunomide. Transplant Proc (1996) 1.02
A non-AUG-defined alternative open reading frame of the intestinal carboxyl esterase mRNA generates an epitope recognized by renal cell carcinoma-reactive tumor-infiltrating lymphocytes in situ. J Immunol (1999) 1.02
The role of interleukin 2 and T11 E rosette antigen in activation and proliferation of human NK clones. J Immunol (1985) 1.02
Natural history of residual renal stone fragments after ESWL. Eur Urol (2000) 1.02
Regulation of expression of the human lymphocyte activation gene-3 (LAG-3) molecule, a ligand for MHC class II. Immunogenetics (1998) 1.02
Diversity of the cytotoxic melanoma-specific immune response: some CTL clones recognize autologous fresh tumor cells and not tumor cell lines. J Immunol (1997) 1.00
T-cell receptor-gamma/delta bearing lymphocytes in normal and inflammatory human skin. J Invest Dermatol (1990) 0.99
Genomic organization of the human LAG-3/CD4 locus. Immunogenetics (1997) 0.98
Degree of bronchial metaplasia in heavy smokers and its regression after treatment with a retinoid. Lancet (1982) 0.98
T cell major histocompatibility complex class II molecules down-regulate CD4+ T cell clone responses following LAG-3 binding. Eur J Immunol (1996) 0.98
T cell repertoire in patients with B chronic lymphocytic leukemia. Evidence for multiple in vivo T cell clonal expansions. J Immunol (1994) 0.97
Identification of a CD2- CD3+ T cell receptor-gamma+ peripheral blood lymphocyte subpopulation. J Immunol (1988) 0.96
Lymphocyte activation gene-3, a MHC class II ligand expressed on activated T cells, stimulates TNF-alpha and IL-12 production by monocytes and dendritic cells. J Immunol (1999) 0.95
A soluble lymphocyte activation gene-3 molecule used as a vaccine adjuvant elicits greater humoral and cellular immune responses to both particulate and soluble antigens. J Immunol (2000) 0.95